Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321537 | 0.87 | ALDH1A1 (0.63) | ALDH1A1PKMLMNASMN1; SMN2CYP19A1 | |
| SCHEMBL6329622 | 0.87 | ALDH1A1 (0.61) | ALDH1A1PKMLMNASMN1; SMN2CYP19A1 | |
| SCHEMBL24269885 | 0.83 | ALDH1A1 (0.56) | ALDH1A1PKMLMNASMN1; SMN2CYP19A1 | |
| SCHEMBL29183278 | 0.83 | ALDH1A1 (0.56) | ALDH1A1PKMLMNASMN1; SMN2CYP19A1 | |
| SCHEMBL15620961 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNACA1CA2MMP1 | |
| SCHEMBL5563528 | 0.82 | ALDH1A1 (0.86) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL27451020 | 0.82 | ALDH1A1 (0.55) | ALDH1A1PKMLMNASMN1; SMN2CYP19A1 | |
| SCHEMBL11251792 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2CA1CA2 | |
| SCHEMBL20730795 | 0.81 | ALDH1A1 (0.77) | ALDH1A1PKMSMN1; SMN2GAAPOLB | |
| SCHEMBL7798915 | 0.81 | ALDH1A1 (0.54) | ALDH1A1PKMLMNASMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-3483143-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3145912-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| EP-2928866-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-104903291-A | Benzyl sulfonamide derivatives as RORc modulators | HOFFMANN LA ROCHE | 2015-09-09 | — | — | CN | disclosed |
| WO-2014090712-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014090712-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0749421-B1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMA (US) | 1999-09-15 | — | — | EP | disclosed |
| EP-0749421-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | ALDH1A1 1145/4885PKM 3867/4885LMNA 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.